Brokers Set Expectations for Intersect ENT Inc’s FY2018 Earnings (XENT)

Intersect ENT Inc (NASDAQ:XENT) – Stock analysts at William Blair lifted their FY2018 earnings estimates for Intersect ENT in a research report issued on Monday. William Blair analyst K. Krum now forecasts that the medical equipment provider will post earnings per share of ($0.46) for the year, up from their previous forecast of ($0.47).

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, October 5th. Guggenheim restated a “buy” rating and set a $41.00 target price on shares of Intersect ENT in a research note on Friday, December 15th. Canaccord Genuity restated a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a research note on Monday, December 11th. BidaskClub cut shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Intersect ENT currently has an average rating of “Buy” and a consensus price target of $33.38.

Intersect ENT (NASDAQ:XENT) traded down $0.30 on Thursday, hitting $34.35. 172,479 shares of the company were exchanged, compared to its average volume of 229,607. Intersect ENT has a 52 week low of $11.75 and a 52 week high of $35.34.

Intersect ENT (NASDAQ:XENT) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The company had revenue of $22.31 million for the quarter, compared to analysts’ expectations of $21.53 million. During the same quarter in the previous year, the company earned ($0.22) EPS. Intersect ENT’s revenue for the quarter was up 20.8% on a year-over-year basis.

In other Intersect ENT news, General Counsel David Aaron Lehman sold 36,000 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $32.75, for a total value of $1,179,000.00. Following the sale, the general counsel now owns 45,000 shares in the company, valued at approximately $1,473,750. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $27.78, for a total transaction of $356,500.74. Following the completion of the sale, the chief financial officer now owns 27,833 shares in the company, valued at approximately $773,200.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,886 shares of company stock worth $3,887,494. Corporate insiders own 13.70% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Legal & General Group Plc increased its holdings in shares of Intersect ENT by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Intersect ENT by 9.7% in the 2nd quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock worth $356,000 after buying an additional 1,128 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Intersect ENT by 5.9% in the 2nd quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock worth $822,000 after buying an additional 1,625 shares during the last quarter. EAM Investors LLC increased its holdings in shares of Intersect ENT by 1.1% in the 3rd quarter. EAM Investors LLC now owns 164,267 shares of the medical equipment provider’s stock worth $5,117,000 after buying an additional 1,776 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Intersect ENT by 4.4% in the 3rd quarter. Nationwide Fund Advisors now owns 56,901 shares of the medical equipment provider’s stock worth $1,772,000 after buying an additional 2,377 shares during the last quarter. Institutional investors and hedge funds own 86.31% of the company’s stock.

WARNING: “Brokers Set Expectations for Intersect ENT Inc’s FY2018 Earnings (XENT)” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/01/13/brokers-set-expectations-for-intersect-ent-incs-fy2018-earnings-xent.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply